Dicarbonyl-Modified Low-Density Lipoproteins Are Key Inducers of LOX-1 and NOX1 Gene Expression in the Cultured Human Umbilical Vein Endotheliocytes

---

Vadim Z. Lankin¹, Mars G. Sharapov^2,a*, Alla K. Tikhaze¹, Ruslan G. Goncharov², Olga A. Antonova¹, Galina G. Konovalova¹, and Vladimir I. Novoselov²

¹Chazov National Medical Research Center for Cardiology, 121552 Moscow, Russia

²Institute of Cell Biophysics, Russian Academy of Sciences, 142290 Pushchino, Moscow Region, Russia

^* To whom correspondence should be addressed.

Received August 25, 2023; Revised September 24, 2023; Accepted September 26, 2023

---

Expression of LOX-1 and NOX1 genes in the human umbilical vein endotheliocytes (HUVECs) cultured in the presence of low-density lipoproteins (LDL) modified with various natural dicarbonyls was investigated for the first time. It was found that among the investigated dicarbonyl-modified LDLs (malondialdehyde (MDA)-modified LDLs, glyoxal-modified LDLs, and methylglyoxal-modified LDLs), the MDA-modified LDLs caused the greatest induction of the LOX-1 and NOX1 genes, as well as of the genes of antioxidant enzymes and genes of proapoptotic factors in HUVECs. Key role of the dicarbonyl-modified LDLs in the molecular mechanisms of vascular wall damage and endothelial dysfunction is discussed.

---

KEY WORDS: low-density lipoproteins (LDL), dicarbonyl-modified LDL, expression of LOX-1 and NOX1 genes, molecular mechanisms of atherogenesis and diabetogenesis

DOI: 10.1134/S0006297923120143

---